Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

DyCE technology is integrated with in vivo molecular imaging system

Cambridge Research And Instrumentation : 24 March, 2008  (New Product)
Cambridge Research and Instrumentation (CRi) has begun shipping its new DyCE (Dynamic Contrast Enhancement) for optical imaging solution to users of the award-winning Maestro in vivo molecular imaging system.
Customers can now generate all-optical anatomical images of mouse models in only a few minutes, saving time and enabling better time-resolved images of molecular probe distribution.

CRi has an exclusive commercialisation agreement with Massachusetts General Hospital (MGH) for its DyCE application.

'DyCE is a quantum leap forward for optical imaging, poised to revolutionise in vivo fluorescence imaging,' said James Mansfield, director of multispectral imaging systems at CRi. 'Our customers can now produce anatomical images in record time and also save significant money versus conventional means.'

Anatomical images are produced using DyCE in the following way. A bolus of an inert near-infrared dye (such as indocyanine green) is injected, and then a time-based series of data is collected. Using CRi's analysis software, this data set is interpreted to delineate most of the major organ systems, using optical imaging alone. This organ-specific imaging is possible, because organs have characteristic uptake or distribution patterns over time that can be 'illuminated' by the dye passing through, distinguishing them from other structures.

These in vivo anatomical maps can be overlaid co-registered with simultaneously acquired images of a targeted molecular probe to delineate the marker's specific anatomical and physical location at any time point in the study.

'CRi is uniquely positioned to commercialise DyCE capitalising on the combination of our advanced multispectral in vivo imaging systems and our industry-leading data analysis tools,' explains George Abe, CRi's president and chief executive officer.

'We are pleased to partner with the Massachusetts General Hospital in this endeavour and are excited to enable our customers to further advance their small animal imaging capabilities', continued Abe.

CRi will exhibit the latest automated Maestro 2 system featuring DyCE along with CRi's cellular imaging solutions at the Annual Meeting of the American Association for Cancer Research (AACR), April 12 to 16, 2008 (Booth 235).
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo